Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Pharma and insurers clash over H.266 340B changes; Blue Cross urges transparency as drug markup in Vermont hospitals alarms payers
Summary
The Senate Health and Welfare Committee heard competing testimony April 10 on H.266, a bill that would alter 340B contract-pharmacy arrangements and add state-level protections and transparency.
The Senate Health and Welfare Committee heard competing testimony April 10 on H.266, a bill that would alter 340B contract-pharmacy arrangements and add state-level protections and transparency. Witnesses sharply disagreed about whether the proposed changes would protect safety-net providers or lock in a model that benefits middlemen.
Morgan Halloran, director for state policy at Pharmaceutical Research and Manufacturers of America (PhRMA), testified that Section 1 of H.266 would “codify a broken model of the 340B program,” saying contract pharmacy arrangements have been increasingly dominated by vertically integrated pharmacy benefit…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
